Nanotechnology and the treatment of inner ear diseases

Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology

Volumn 3, Issue 2, 2011, Pages 212-221

  Poe, Dennis S ^a,b,c   Pyykkö, Ilmari ^a  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFFECTIVE DOSE; EPITHELIAL CELLS; INNER EAR; NERVE CELLS; NEURAL CELLS; SENSORINEURAL HEARING LOSS; SIDE EFFECT; SUSTAINED RELEASE; THERAPEUTIC AGENTS;

CELLS; CYTOLOGY; DRUG DOSAGE; DRUG INTERACTIONS; GENE THERAPY; GENETIC ENGINEERING; NANOPARTICLES; NEURONS;

AUDITION;

BRAIN DERIVED NEUROTROPHIC FACTOR; NANOPARTICLE; NERVE GROWTH FACTOR; NEUROTROPHIN 3; STEROID;

ARTICLE; CONTRAST ENHANCEMENT; DRUG DELIVERY SYSTEM; EARDRUM; GENE THERAPY; HUMAN; IN VIVO STUDY; INNER EAR DISEASE; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; ANATOMY AND HISTOLOGY; ANIMAL; INNER EAR; LABYRINTH DISEASES; MEDICAL RESEARCH; NANOMEDICINE; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

ANIMALS; BIOMEDICAL RESEARCH; EAR, INNER; HUMANS; LABYRINTH DISEASES; NANOMEDICINE;

EID: 79551694482     PISSN: 19395116     EISSN: 19390041     Source Type: Journal    
DOI: 10.1002/wnan.125     Document Type: Article

References (60)

1. Zou J, Ramadan UA, Pyykko I. Gadolinium uptake in the rat inner ear perilymph evaluated with 4.7 T MRI: a comparison between transtympanic injection and gelatin sponge-based diffusion through the round window membrane. Otol Neurotol 2010, 31:637-641.
2. Juhn SK. Barrier systems in the inner ear. Acta Otolaryngol Suppl 1988, 458:79-83.
3. Juhn SK, Rybak LP. Labyrinthine barriers and cochlear homeostasis. Acta Otolaryngol 1981, 91:529-534.
4. Zou J, Pyykko I, Counter SA, Klason T, Bretlau P, Bjelke B. In vivo observation of dynamic perilymph formation using 4.7 T MRI with gadolinium as a tracer. Acta Otolaryngol 2003, 123:910-915.
5. Van de Water TR, Staecker H, Halterman MW, Federoff HJ. Gene therapy in the inner ear. Mechanisms and clinical implications. Ann N Y Acad Sci 1999, 884:345-360.
6. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des 2007, 13:119-126.
7. Wilson WR, Schuknecht HF. Update on the use of streptomycin therapy for Meniere's disease. Am J Otol 1980, 2:108-111.
8. Moskowitz D, Lee KJ, Smith HW. Steroid use in idiopathic sudden sensorineural hearing loss. Laryngoscope 1984, 94:664-666.
9. Chia SH, Gamst AC, Anderson JP, Harris JP. Intratympanic gentamicin therapy for Meniere's disease: a meta-analysis. Otol Neurotol 2004, 25:544-552.
10. Parnes LS, Sun AH, Freeman DJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 1999, 109:1-17.
11. Silverstein H, Wazen J, Van Ess MJ, Daugherty J, Alameda YA. Intratympanic gentamicin treatment of patients with Meniere's disease with normal hearing. Otolaryngol Head Neck Surg 2010, 142:570-575.
12. Hahn H, Kammerer B, DiMauro A, Salt AN, Plontke SK. Cochlear microdialysis for quantification of dexamethasone and fluorescein entry into scala tympani during round window administration. Hear Res 2006, 212:236-244.
13. Hornyak GL. Nanotechnology in otolaryngology. Otolaryngol Clin North Am 2005, 38:273-293, vi.
14. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009, 66:2873-2896.
15. Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, DeSimone JM. The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci U S A 2008, 105:11613-11618.
16. Jiang W, Kim BY, Rutka JT, Chan WC. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 2008, 3:145-150.
17. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008, 5:496-504.
18. Goycoolea MV, Lundman L. Round window membrane. Structure function and permeability: a review. Microsc Res Tech 1997, 36:201-211.
19. Balda MS, Matter K. Tight junctions. J Cell Sci 1998, 111 (Pt 5):541-547.
20. Spring KR. Routes and mechanism of fluid transport by epithelia. Annu Rev Physiol 1998, 60:105-119.
21. Tsukita S, Furuse M, Itoh M. Structural and signalling molecules come together at tight junctions. Curr Opin Cell Biol 1999, 11:628-633.
22. Knorr V, Allmendinger L, Walker GF, Paintner FF, Wagner E. An acetal-based PEGylation reagent for pH-sensitive shielding of DNA polyplexes. Bioconjug Chem 2007, 18:1218-1225.
23. Nam HY, Kwon SM, Chung H, Lee SY, Kwon SH, Jeon H, Kim Y, Park JH, Kim J, Her S, et al. Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release 2009, 135:259-267.
24. Rosenholm JM, Peuhu E, Eriksson JE, Sahlgren C, Linden M. Targeted intracellular delivery of hydrophobic agents using mesoporous hybrid silica nanoparticles as carrier systems. Nano Lett 2009, 9:3308-3311.
25. Mozafari MR. Liposomes: an overview of manufacturing techniques. Cell Mol Biol Lett 2005, 10:711-719.
26. Lee RJ, Huang L. Lipidic vector systems for gene transfer. Crit Rev Ther Drug Carrier Syst 1997, 14:173-206.
27. Deda DK, Uchoa AF, Carita E, Baptista MS, Toma HE, Araki K. A new micro/nanoencapsulated porphyrin formulation for PDT treatment. Int J Pharm 2009, 376:76-83.
28. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. The influence of lipid nanocapsule composition on their size distribution. Eur J Pharm Sci 2003, 18:55-61.
29. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res 2002, 19:875-880.
30. Qin J, Jo YS, Ihm JE, Kim do K, Muhammed M. Thermosensitive nanospheres with a gold layer revealed as low-cytotoxic drug vehicles. Langmuir 2005, 21:9346-9351.
31. Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 2007, 65:259-269.
32. Christian NA, Milone MC, Ranka SS, Li G, Frail PR, Davis KP, Bates FS, Therien MJ, Ghoroghchian PP, June CH, et al. Tat-functionalized near-infrared emissive polymersomes for dendritic cell labeling. Bioconjug Chem 2007, 18:31-40.
33. Hsiao JK, Tsai CP, Chung TH, Hung Y, Yao M, Liu HM, Mou CY, Yang CS, Chen YC, Huang DM. Mesoporous silica nanoparticles as a delivery system of gadolinium for effective human stem cell tracking. Small 2008, 4:1445-1452.
34. Liu HM, Wu SH, Lu CW, Yao M, Hsiao JK, Hung Y, Lin YS, Mou CY, Yang CS, Huang DM, et al. Mesoporous silica nanoparticles improve magnetic labeling efficiency in human stem cells. Small 2008, 4:619-626.
35. Fu A, Gu W, Larabell C, Alivisatos AP. Semiconductor nanocrystals for biological imaging. Curr Opin Neurobiol 2005, 15:568-575.
36. Qin J, Asempah I, Laurent S, Fornara A, Muller RN, Muhammed M. Injectable superparamagnetic ferrogels for controlled release of hydrophobic drugs. Adv Mater 2009, 21:1354-1357.
37. Fornara A, Johansson P, Petersson K, Gustafsson S, Qin J, Olsson E, Ilver D, Krozer A, Muhammed M, Johansson C. Tailored magnetic nanoparticles for direct and sensitive detection of biomolecules in biological samples. Nano Lett 2008, 8:3423-3428.
38. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001, 11:2319-2331.
39. Kiessling F. Noninvasive cell tracking In: Schwaiger WSaM, ed. Molecular Imaging II Handbook of Experimental Pharmacology 185/II. Berlin, Heidelberg: Springer-Verlag; 2008, 305-321.
40. Qin J, Jo YS, Muhammed M. Coating nanocrystals with amphiphilic thermosensitive copolymers. Angew Chem Int Ed Engl 2009, 48:7845-7849.
41. Wareing M, Mhatre AN, Pettis R, Han JJ, Haut T, Pfister MH, Hong K, Zheng WW, Lalwani AK. Cationic liposome mediated transgene expression in the guinea pig cochlea. Hear Res 1999, 128:61-69.
42. Staecker H, Li D, O'Malley BW Jr, Van De Water TR. Gene expression in the mammalian cochlea: a study of multiple vector systems. Acta Otolaryngol 2001, 121:157-163.
43. Chen G, Hou SX, Hu P, Hu QH, Guo DD, Xiao Y. In vitro dexamethasone release from nanoparticles and its pharmacokinetics in the inner ear after administration of the drug-loaded nanoparticles via the round window. Nan Fang Yi Ke Da Xue Xue Bao 2008, 28:1022-1024.
44. Zou J, Saulnier P, Perrier T, Zhang Y, Manninen T, Toppila E, Pyykko I. Distribution of lipid nanocapsules in different cochlear cell populations after round window membrane permeation. J Biomed Mater Res B Appl Biomater 2008, 87:10-18.
45. Tamura T, Kita T, Nakagawa T, Endo T, Kim TS, Ishihara T, Mizushima Y, Higaki M, Ito J. Drug delivery to the cochlea using PLGA nanoparticles. Laryngoscope 2005, 115:2000-2005.
46. Praetorius M, Brunner C, Lehnert B, Klingmann C, Schmidt H, Staecker H, Schick B. Transsynaptic delivery of nanoparticles to the central auditory nervous system. Acta Otolaryngol 2007, 127:486-490.
47. Ge X, Jackson RL, Liu J, Harper EA, Hoffer ME, Wassel RA, Dormer KJ, Kopke RD, Balough BJ. Distribution of PLGA nanoparticles in chinchilla cochleae. Otolaryngol Head Neck Surg 2007, 137:619-623.
48. Knight VB, Serrano EE. Tissue and species differences in the application of quantum dots as probes for biomolecular targets in the inner ear and kidney. IEEE Trans Nanobioscience 2006, 5:251-262.
49. Roy S, Johnston AH, Newman TA, Glueckert R, Dudas J, Bitsche M, Corbacella E, Rieger G, Martini A, Schrott-Fischer A. Cell-specific targeting in the mouse inner ear using nanoparticles conjugated with a neurotrophin-derived peptide ligand: potential tool for drug delivery. Int J Pharm 2010, 390:214-224.
50. Kujawa SG, Liberman MC. Adding insult to injury: cochlear nerve degeneration after "temporary" noise-induced hearing loss. J Neurosci 2009, 29: 14077-14085.
51. Kopke RD, Wassel RA, Mondalek F, Grady B, Chen K, Liu J, Gibson D, Dormer KJ. Magnetic nanoparticles: inner ear targeted molecule delivery and middle ear implant. Audiol Neurootol 2006, 11:123-133.
52. Yamasoba T, Nuttall AL, Harris C, Raphael Y, Miller JM. Role of glutathione in protection against noise-induced hearing loss. Brain Res 1998, 784:82-90.
53. Tessarollo L, Coppola V, Fritzsch B. NT-3 replacement with brain-derived neurotrophic factor redirects vestibular nerve fibers to the cochlea. J Neurosci 2004, 24:2575-2584.
54. Ernfors P, Van De Water T, Loring J, Jaenisch R. Complementary roles of BDNF and NT-3 in vestibular and auditory development. Neuron 1995, 14:1153-1164.
55. Crumling MA, Raphael Y. Manipulating gene expression in the mature inner ear. Brain Res 2006, 1091:265-269.
56. Izumikawa M, Minoda R, Kawamoto K, Abrashkin KA, Swiderski DL, Dolan DF, Brough DE, Raphael Y. Auditory hair cell replacement and hearing improvement by Atoh1 gene therapy in deaf mammals. Nat Med 2005, 11:271-276.
57. Zou J, Zhang W, Poe D, Zhang Y, Ramadan UA, Pyykko I. Differential passage of gadolinium through the mouse inner ear barriers evaluated with 4.7 T MRI. Hear Res 2010, 259:36-43.
58. Zou J, Poe D, Bjelke B, Pyykko I. Visualization of inner ear disorders with MRI in vivo: from animal models to human application. Acta Otolaryngol Suppl 2009, 560:22-31.
59. Qin J, Laurent S, Suk JY, Roch A, Mikhaylova M, Bhujwalla ZM, Robert MM, Muller N. A high-performance magnetic resonance imaging T2 contrast agent. Adv Mater 2007, 19:1874-1878.
60. Poe P, Zou J, Zhang W, Qin J, Abo Ramadan U, Fornara A, Muhammed M, Pyykkö I. MRI of the cochlea with superparamagnetic iron oxide nanoparticles compared to gadolinium chelate contrast agents in a rat model. Eur J Nanomed 2009, 2:29-36.